Saturday 17 October 2026
Export OVID’s income statement to Excel — free account
Ovid Therapeutics
OVID Healthcare Biotechnology
Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024. In the quarter to June 2026, revenue grew 463.9%, EPS fell 33.3%, free cash flow fell 268.5% and total debt fell 11.7%, each against the same quarter a year earlier.
2.15
0.11
−4.87%
Follow OVID
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | 0.00 |
P/S ratio |
13.99 | 16.57 | — | 67.62 | |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 | |
P/Operating CF |
(7.18) | (11.55) | — | (30.19) | |
P/B ratio |
2.07 | 0.92 | — | 2.53 | |
Price to Tangible BV |
2.07 | 0.92 | — | 2.53 | |
EV/Sales |
11.98 | 8.62 | — | 54.13 | |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | |
EV/Operating CF |
(2.09) | (1.63) | — | (7.76) | |
EV/FCF |
(2.08) | (1.63) | — | (7.74) | |
Quick Ratio |
3.77 | 8.40 | 9.88 | 11.75 | |
Current Ratio |
4.24 | 8.97 | 10.17 | 12.39 | |
Net Debt/EBITDA |
1.06 | 4.70 | 8.08 | 6.76 | |
Debt/Assets |
19.35% | 7.94% | 5.15% | 4.84% | |
Debt/Equity |
0.28 | 0.09 | 0.06 | 0.05 | |
Asset Turnover |
0.08 | 0.06 | 0.00 | 0.05 | |
Operating CF/Net income |
1.06 | (1.08) | 0.82 | 1.17 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,446.97% | 917.55% | 0.00% | 1,358.39% | |
Selling, General and Administrative Expense of Revenue |
5,140.15% | 894.57% | 0.00% | 883.22% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
840.15% | 166.43% | 0.00% | 195.23% | |
Graham Net Nets |
0.10 | 0.45 | — | 0.19 | |
Graham Number |
0.00 | 0.00 | — | 0.00 | |
Earnings Yield |
(38.46%) | (13.82%) | — | (8.38%) | |
Free Cash Flow Yield |
(41.19%) | (32.02%) | — | (10.34%) | |
Revenue per Share |
0.00 | 0.01 | 0.00 | 0.00 | |
Operating CF per Share |
(0.18) | (0.14) | (0.10) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.14) | (0.10) | (0.09) | |
Cash per Share |
0.36 | 0.94 | 1.14 | 0.59 | |
Shareholders Equity per Share |
0.63 | 1.77 | 1.46 | 1.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.63 | 1.77 | 1.46 | 1.06 | |
Free Cash Flow |
(12.87) | (10.41) | (13.90) | (17.59) | |
Working Capital |
22.03 | 66.08 | 144.40 | 113.64 | |
Net Current Asset Value |
9.67 | 54.09 | 132.79 | 101.53 | |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | |
| Other line items | |||||
Average Payables |
2.21 | 2.57 | 5.41 | 4.01 | |
Average Assets |
83.25 | 121.55 | 153.64 | 154.70 | |
Average Common Equity |
60.49 | 99.44 | 128.77 | 132.84 |
Columns are period end dates